Table 1 Clinicopathological characteristics of patients enrolled in this study.

From: Machine learning-based radiomics strategy for prediction of acquired EGFR T790M mutation following treatment with EGFR-TKI in NSCLC

Variable

Training cohort

p

Validation cohort

p

p

T790M-positive (N = 90)

T790M-negative (N = 102)

 

T790M-positive (N = 38)

T790M-negative (N = 44)

  

Age (y, mean ± SD)

65.30 ± 9.90

64.16 ± 10.72

0.45

65.26 ± 10.81

66.11 ± 10.98

0.73

0.46

Sex, n (%)

  

0.04

  

0.03

0.01

 Male

52 (57.78)

43 (42.16)

 

26 (68.42)

19 (43.18)

  

 Female

38 (42.22)

59 (57.84)

 

12 (31.58)

25 (56.82)

  

Smoking Status, n (%)

  

0.66

  

0.82

0.06

 Smoker

47 (52.22)

49 (48.04)

 

20 (52.63)

21 (47.73)

  

 Never smoker

43 (47.78)

53 (51.96)

 

18 (47.37)

23 (52.27)

  

Performance status (at biopsy)

  

0.55

  

0.65

0.05

 0–1

57 (63.33)

69 (67.65)

 

24 (63.16)

30 (68.18)

  

  ≥ 2

33 (36.67)

33 (32.35)

 

14 (36.84)

14 (31.82)

  

Pathological type

  

0.69

  

0.64

0.94

 Adenocarcinoma

85 (94.45)

96 (94.12)

 

36 (94.74)

41 (93.18)

  

 Adenosquamous carcinoma

3 (3.33)

5 (4.90)

 

2 (5.26)

2 (4.55)

  

 Squamous carcinoma

2 (2.22)

1 (0.98)

 

0 (0.00)

1 (2.27)

  

Stage, n (%)

  

0.72

  

0.79

0.87

 III

20 (22.22)

20 (19.61)

 

8 (21.05)

8 (18.18)

  

 IV

70 (77.78)

82 (80.39)

 

30 (76.95)

36 (81.82)

  

EGFR mutation

  

0.30

  

0.50

0.89

 Exon 19 deletion

53 (58.89)

68 (66.67)

 

22 (57.89)

29 (65.91)

  

 Exon 21 L858R

37 (41.11)

34 (33.33)

 

16 (42.11)

15 (34.09)

  

Serum level of tumor marker (mean ± SD)

       

 CEA

68.33 ± 85.64

59.56 ± 84.91

0.48

43.91 ± 42.51

48.66 ± 63.23

0.69

0.09

 NSE

18.08 ± 19.38

15.11 ± 6.20

0.14

20.33 ± 23.13

21.62 ± 43.28

0.87

0.13

 CYFRA 21–1

5.35 ± 6.69

3.25 ± 3.43

0.01

4.19 ± 3.90

5.20 ± 5.78

0.36

0.47

 SCC

0.93 ± 0.88

0.96 ± 1.02

0.82

0.73 ± 0.42

0.72 ± 0.47

0.93

0.04

 Pro-GRP

47.68 ± 51.69

42.69 ± 44.04

0.47

51.15 ± 68.95

38.81 ± 13.09

0.23

0.90

Initial EGFR-TKI response

  

0.02

  

0.01

0.04

 CR or PR

65 (72.22)

57 (55.88)

 

33 (86.84)

26 (59.09)

  

 SD or PD

25 (27.78)

45 (44.12)

 

5 (13.16)

18 (40.91)

  
  1. EGFR epidermal growth factor receptor, CEA carcinoembryonic antigen, NSE neuron-specific enolase, CYFRA 21–1 fragment of cytokeratin subunit 19, SCC squamous cell carcinoma antigen, Pro-GRP pro-gastrin-releasing peptide, CR complete response, PR partial response, SD stable disease, PD progressive disease.
Back to article page